• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Going Mad for CROs

Going Mad for CROs

January 15, 2008
CenterWatch Staff

Public, global contract research organizations (CROs) are having a great run with stock prices soaring and their global growth story intact. The sector got additional validation Jan. 14 when “Mad Money” host Jim Cramer featured the niche. In general, star stock picker Cramer got the story straight on CROs, even though a few times he mispronounced company names. That happens, but at least he got the stock symbols right. And that is what counts. You can watch a replay of the episode here.

Here’s the story that CenterWatch has been covering since the beginning of time, or sometime around 1994:

Pharmaceutical companies are continuing to outsource their clinical trials in a greater percentage to CROs. And now many of those trials are going overseas. The handful of global CROs, including the largest (private, but formerly public Quintiles) have the infrastructure in place worldwide to handle those large trials. It isn’t an easy thing to build quickly so there is a barrier to entry.

Cramer said the sector is a good defensive play in a tough overall stock market. CROs, he said, would continue to grow because pharmaceutical companies desperately need to bring more drugs to market. And CROs can do the job much more cheaply than pharma companies that develop drugs in-house. We have always said that clinical research is hard work and Cramer made a good point that CROs do it better than pharma and biotech companies because they are doing it every day. Hard work done every day creates expertise.

Cramer’s picks? His favorite is Covance (CVD for you home gamers) because of its strength at opposite ends of the pipeline—in both preclinical and late phase. He also gave a thumbs up to Parexel with its expertise in late phase. Charles River got the Cramer nod as a pure-play preclinical company.

There’s always a bull market somewhere…

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing